Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of CKD-510 Tablet vs Capsule in Healthy Subjects
NCT05526742Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-510 in Charcot-Marie-Tooth disease (CMT) and Atrial fibrillation (AFib) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Plasma Maximum Observed Concentration (Cmax), Area Under the Curve (AUC) and 3 more. Started Aug 2022; status: completed.
02
Drugs
CKD-510
03
Conditions
Charcot-Marie-Tooth disease (CMT)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05526742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526742.